View More Recent Stories
-
Notable Analyst Rating Changes 5/6: DIS, IGT, AEO, AZO Upgraded; BCS, FITB, VCLK, CBL Downgraded
-
Highlights From Amgen's (AMGN) Q1 Conference Call: Guides Lower for FY09 Revenues
-
Notable Analyst Rating Changes 4/24: RIMM, AMGN, INFA, CAKE Upgraded; MAR, SPWRA, TOL, PTR Downgraded
-
David Moenning's Daily State of the Markets: 4/24
-
David Moenning's Daily State of the Markets: 4/13
-
Citigroup (C) and GM (GM) Out of The Global Dow, Is Dow 30 Next?
-
Citi Reiterates a 'Buy' Rating on Teva Pharmaceutical (TEVA)
-
David Moenning's Daily State of the Markets: 3/6
-
David Moenning's Daily State of the Markets: 1/27
-
David Moenning's Daily State of the Markets: 1/23
-
Citi Maintains 'Buy' Rating on Amgen (AMGN), Adds Stock to Top Picks Live List
-
David Moenning's Daily State of the Markets: 10/23
-
David Moenning's Daily State of the Markets: 7/30
-
Notable Analyst Rating Changes 7/29: AMGN, AFL, DPS Upgraded; VNDA, ZRAN, SNDK Downgraded
-
David Moenning’s Daily State of the Markets: 07/29
-
Citi Upgrades Amgen (AMGN) to Buy
-
Equity option family volume leaders in first 30-minutes of Trading: BAC JPM AMGN C
-
David Moenning's Daily State of the Markets: 4/25
-
David Moenning's Daily State of the Markets: 3/18
-
Citi Maintains 'Hold' Rating on Amgen (AMGN), Comments on FDA Briefing Documents
-
Citi Analyst Comments on Court Decision Between Amgen (AMGN) and Roche
-
David Moenning's Daily State of the Markets: 1/25

